{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:41:17Z","timestamp":1791996077524,"version":"4.4.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-12560-y","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T13:48:58Z","timestamp":1771508938000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Continuous versus intermittent vancomycin infusions in critically ill children with gram-positive bacterial infections: a randomized controlled trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Yahui","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodai","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingrong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihui","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"12560_CR1","doi-asserted-by":"crossref","unstructured":"Crompton JA, North DS, Minjung Y, et al. Outcomes with daptomycin in the treatment of Staphylococcus aureus infections with a range of Vancomycin MICs[J]. J Antimicrob Chemother. 2010;65(8):1784.","DOI":"10.1093\/jac\/dkq200"},{"issue":"6","key":"12560_CR2","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1128\/AAC.03970-14","volume":"59","author":"AM Casapao","year":"2015","unstructured":"Casapao AM, Lodise TP, Davis SL, et al. Association between Vancomycin day 1 exposure profile and outcomes among patients with Methicillin-Resistant Staphylococcus aureus infective endocarditis. Antimicrob Agents Chemother. 2015;59(6):2978\u201385.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"12560_CR3","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/cid\/civ808","volume":"62","author":"JS Davis","year":"2016","unstructured":"Davis JS, for the Australasian Society for Infectious Diseases Clinical Research N, Sud A, et al. Combination of Vancomycin and \u03b2-Lactam therapy for Methicillin-Resistant Staphylococcus aureus bacteremia: A pilot multicenter randomized controlled trial. Clin Infect Dis. 2016;62(2):173\u201380.","journal-title":"Clin Infect Dis"},{"key":"12560_CR4","doi-asserted-by":"crossref","unstructured":"Petrarca A, Burant C, Stiefel U, et al. Outcomes of bloodstream infections (BSI) caused by Coagulase-Negative Staphylococcus (CoNS) with elevated minimum inhibitory concentration (MIC) to Vancomycin at a tertiary care veterans affairs (VA) medical center. Open Forum Infect Dis. 2016.","DOI":"10.1093\/ofid\/ofw172.793"},{"key":"12560_CR5","unstructured":"Yu FF, Luo ZX. Individualized anti-infectious therapeutic strategies of van-comycin in children with community-acquired methicillin-resistant Staphylococcus aureus pneumonia [J]. Chin J Pract Pediatr. 2022;(2):99\u2013103."},{"key":"12560_CR6","first-page":"606","volume":"3","author":"MH McCormick","year":"1955","unstructured":"McCormick MH, McGuire JM, Pittenger GE, et al. Vancomycin, a new antibiotic. I. Chemical and biologic properties[J]. Antibiot Annu. 1955;3:606\u201311.","journal-title":"Antibiot Annu"},{"key":"12560_CR7","doi-asserted-by":"crossref","unstructured":"Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, Mueller BA, Pai MP, Wong-Beringer A, Rotschafer JC, Rodvold KA, Maples HD, Lomaestro B. Therapeutic monitoring of Vancomycin for serious Methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American society of Health-system pharmacists, the infectious diseases society of America, the pediatric infectious diseases society, and the society of infectious diseases pharmacists. Volume 71. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2020;1361\u20134. 6.","DOI":"10.1093\/cid\/ciaa303"},{"issue":"Suppl 4","key":"12560_CR8","doi-asserted-by":"publisher","first-page":"S363","DOI":"10.1093\/cid\/ciaa1536","volume":"71","author":"N He","year":"2020","unstructured":"He N, Su S, Ye Z, et al. Evidence-based guideline for therapeutic drug monitoring of vancomycin: 2020 update by the division of therapeutic drug monitoring, Chinese Pharmacological society. Clin Infect Dis. 2020;71(Suppl 4):S363\u201371.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"12560_CR9","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1097\/CCM.0000000000004326","volume":"48","author":"AH Flannery","year":"2020","unstructured":"Flannery AH, Bissell BD, Bastin MT, Morris PE, Neyra JA. Continuous versus intermittent infusion of Vancomycin and the risk of acute kidney injury in critically ill adults: A systematic review and Meta-Analysis. Crit Care Med. 2020;48(6):912\u20138.","journal-title":"Crit Care Med"},{"issue":"6","key":"12560_CR10","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1177\/0885066618768749","volume":"35","author":"BD Bissell","year":"2020","unstructured":"Bissell BD, Riggi G, Morrison C. Evaluation of continuous infusion Vancomycin administration in a critically ill trauma population. J Intensive Care Med. 2020;35(6):570\u20135.","journal-title":"J Intensive Care Med"},{"key":"12560_CR11","doi-asserted-by":"publisher","first-page":"7751","DOI":"10.2147\/IDR.S395385","volume":"15","author":"C Maluangnon","year":"2022","unstructured":"Maluangnon C, Tongyoo S, Permpikul C. Continuous Vancomycin infusion versus intermittent infusion in critically ill patients. Infect Drug Resist. 2022;15:7751\u201360.","journal-title":"Infect Drug Resist"},{"issue":"1","key":"12560_CR12","doi-asserted-by":"publisher","first-page":"e145933","DOI":"10.5812\/ijpr-145933","volume":"23","author":"NSB Roshan","year":"2024","unstructured":"Roshan NSB, Mirrahimi B, Najmeddin F, et al. Comparison of the areas under the curve of Vancomycin continuous vs. Intermittent infusion in critically ill pediatrics: A randomized clinical trial. Iran J Pharm Res. 2024;23(1):e145933.","journal-title":"Iran J Pharm Res"},{"issue":"3","key":"12560_CR13","first-page":"198","volume":"25","author":"HL Girand","year":"2020","unstructured":"Girand HL. Continuous infusion Vancomycin in pediatric patients: A critical review of the evidence. J Pediatr Pharmacol Ther. 2020;25(3):198\u2013214.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"2","key":"12560_CR14","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1093\/jpids\/piy032","volume":"8","author":"AL Hurst","year":"2019","unstructured":"Hurst AL, Baumgartner C, MacBrayne CE, Child J. Experience with continuous infusion Vancomycin dosing in a large pediatric hospital. J Pediatr Infect Dis Soc. 2019;8(2):174\u20139.","journal-title":"J Pediatr Infect Dis Soc"},{"key":"12560_CR15","unstructured":"Bruniera FR, Ferreira FM, Saviolli LRM, et al. The use of Vancomycin with its therapeutic and adverse effects: a review[J]. 2015;19(4):694\u2013700."},{"issue":"2","key":"12560_CR16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ijantimicag.2010.10.013","volume":"37","author":"A Wong-Beringer","year":"2011","unstructured":"Wong-Beringer A, Joo J, Tse E, et al. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy[J]. Int J Antimicrob Agents. 2011;37(2):95\u2013101.","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"12560_CR17","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1159\/000503418","volume":"12","author":"NE Ajit","year":"2019","unstructured":"Ajit NE, Devarashetty SP, Master S. Vancomycin induced Thrombocytopenia - Protracted course in a Hemodialysis Patient[J]. Case Rep Oncol. 2019;12(3):749\u201354.","journal-title":"Case Rep Oncol"},{"key":"12560_CR18","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jpba.2019.05.056","volume":"174","author":"M Zhang","year":"2019","unstructured":"Zhang M, Huang XL, Yahui W, et al. A rapid and simple UPLC method for serum Vancomycin determination in pediatric patients undergoing continuous infusion or intermittent infusion of Vancomycin[J]. J Pharm Biomed Anal. 2019;174:214\u20139.","journal-title":"J Pharm Biomed Anal"},{"key":"12560_CR19","volume-title":"British National formulary for children 2023\u20132024","author":"Paediatric Formulary Committee","year":"2023","unstructured":"Paediatric Formulary Committee. British National formulary for children 2023\u20132024. London, UK: Pharmaceutical; 2023."},{"issue":"9","key":"12560_CR20","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1128\/AAC.45.9.2460-2467.2001","volume":"45","author":"M Wysocki","year":"2001","unstructured":"Wysocki M, Delatour F, Faurisson F, et al. Continuous versus intermittent infusion of Vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother. 2001;45(9):2460\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"12560_CR21","unstructured":"National Health and Family Planning Commission of China. the Guiding Principles of Clinical Use of Antibiotics. Official website of the National Health and Family Planning Commission,China. 2015."},{"issue":"2","key":"12560_CR22","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1128\/AAC.01088-08","volume":"53","author":"A Forouzesh","year":"2009","unstructured":"Forouzesh A, Moise PA, Sakoulas G. Vancomycin ototoxicity: a Reevaluation in an era of increasing doses. Antimicrob Agents Chemother. 2009;53(2):483\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"19","key":"12560_CR23","first-page":"83","volume":"26","author":"WANG Shanshan","year":"2022","unstructured":"Shanshan WANG, Li XU, Zehui CHEN, Ling LI, Yun LIU. Single center study on clinical distribution and drug resistance analysis of Staphylococcus aureus[J]. J Clin Med Pract. 2022;26(19):83\u20136.","journal-title":"J Clin Med Pract"},{"issue":"1","key":"12560_CR24","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s12887-023-04175-y","volume":"23","author":"D Chen","year":"2023","unstructured":"Chen D, Cao L, Li W. Etiological and clinical characteristics of severe pneumonia in pediatric intensive care unit (PICU). [J] BMC Pediatr. 2023;23(1):362.","journal-title":"[J] BMC Pediatr"},{"issue":"10","key":"12560_CR25","first-page":"676","volume":"24","author":"JC Sun","year":"2024","unstructured":"Sun JC, Dai LB, Yang HX. Research progress on therapeutic drug monitoring and individualized drug administration of Vancomycin [J]. Chin J Drugs Clin. 2024;24(10):676\u201380.","journal-title":"Chin J Drugs Clin"},{"issue":"6","key":"12560_CR26","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2165\/0148581-200810060-00004","volume":"10","author":"JG Newland","year":"2008","unstructured":"Newland JG, Kearns GL. Treatment strategies for methicillin-resistant Staphylococcus aureus infections in pediatrics. Paediatr Drugs. 2008;10(6):367\u201378.","journal-title":"Paediatr Drugs"},{"issue":"1","key":"12560_CR27","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/INF.0000000000003349","volume":"41","author":"J Camacho-Cruz","year":"2022","unstructured":"Camacho-Cruz J, Guti\u00e9rrez IF, Brand-L\u00f3pez K, et al. Differences between Methicillin-susceptible versus Methicillin-resistant Staphylococcus aureus infections in pediatrics: multicenter cohort study conducted in Bogot\u00e1, Colombia, 2014\u20132018. Pediatr Infect Dis J. 2022;41(1):12\u20139.","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"12560_CR28","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12887-016-0753-0","volume":"16","author":"H Padari","year":"2016","unstructured":"Padari H, Oselin K, Tasa T, Metsvaht T, L\u00f5ivukene K, Lutsar I. Coagulase negative Staphylococcal sepsis in neonates: do we need to adapt Vancomycin dose or target? BMC Pediatr. 2016;16(1):206.","journal-title":"BMC Pediatr"},{"issue":"5","key":"12560_CR29","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/FTD.0000000000000190","volume":"37","author":"A Hahn","year":"2015","unstructured":"Hahn A, Frenck RW Jr, Allen-Staat M, Zou Y, Vinks AA. Evaluation of target attainment of Vancomycin area under the curve in children with Methicillin-Resistant Staphylococcus aureus bacteremia. Ther Drug Monit. 2015;37(5):619\u201325.","journal-title":"Ther Drug Monit"},{"issue":"4","key":"12560_CR30","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.bjid.2020.07.001","volume":"24","author":"CH Yamada","year":"2020","unstructured":"Yamada CH, Telles JP, Oliveira DDS, et al. Comparison of intermittent versus continuous-infusion Vancomycin for treating severe patients in intensive care units. Braz J Infect Dis. 2020;24(4):356\u20139.","journal-title":"Braz J Infect Dis"},{"issue":"1","key":"12560_CR31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00228-023-03585-2","volume":"80","author":"D Gilliam","year":"2024","unstructured":"Gilliam D, Acosta D, Carvour ML, Walraven C. Retrospective review of intermittent and continuous infusion Vancomycin for methicillin-resistant Staphylococcus aureus bacteremia. Eur J Clin Pharmacol. 2024;80(1):75\u201381.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"12560_CR32","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1128\/AAC.01602-07","volume":"52","author":"TP Lodise","year":"2008","unstructured":"Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger Vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008;52(4):1330\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"12560_CR33","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.jiph.2015.01.011","volume":"8","author":"S Tafelski","year":"2015","unstructured":"Tafelski S, Nachtigall I, Troeger U, et al. Observational clinical study on the effects of different dosing regimens on Vancomycin target levels in critically ill patients: continuous versus intermittent application[J]. J Infect Public Health. 2015;8(4):355\u201363.","journal-title":"J Infect Public Health"},{"issue":"1","key":"12560_CR34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/jac\/dkr442","volume":"67","author":"CM Adriana","year":"2012","unstructured":"Adriana CM, Evelina T, Elisabetta G, et al. Continuous versus intermittent infusion of Vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis[J]. J Antimicrob Chemother. 2012;67(1):17\u201324.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"12560_CR35","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1128\/AAC.02564-13","volume":"58","author":"W Zhao","year":"2014","unstructured":"Zhao W, Zhang D, Fakhoury M. Et a1. Population pharmacokinetics and dosing optimization of Vancomycin in children with malignant hematological disease[J]. Antimicrob Agents Chemother. 2014;58(6):3191\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"12560_CR36","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.bjid.2012.06.011","volume":"16","author":"D\u00e1fneTF Seixas","year":"2012","unstructured":"Cardoso Bourguignon da Silva, Seixas D\u00e1fneTF, Gl\u00e1ucia, Orlei RDA, et al. Vancomycin serum concentrations in pediatric oncologic\/ hematologic intensive care patients[J]. Brazilian J Infect Dis. 2012;16(4):361\u20135.","journal-title":"Brazilian J Infect Dis"},{"key":"12560_CR37","doi-asserted-by":"publisher","first-page":"10651069","DOI":"10.1093\/jac\/dkn288","volume":"62","author":"IY Lubenko","year":"2008","unstructured":"Lubenko IY, Strukova EV, Smirnova MV, Vostrov SN, Portnoy YA, Zinner SH, et al. Telavancin and Vancomycin pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model. J Antimicrob Chemother. 2008;62:10651069.","journal-title":"J Antimicrob Chemother"},{"key":"12560_CR38","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2165\/00003088-200443130-00005","volume":"43","author":"PA Moise-Broder","year":"2004","unstructured":"Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of Vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43:925\u201342.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"12560_CR39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12941-016-0135-3","volume":"15","author":"A Kassim","year":"2016","unstructured":"Kassim A, Omuse G, Premji Z, et al. Comparison of clinical laboratory standards Institute and European committee on antimicrobial susceptibility testing guidelines for the interpretation of antibiotic susceptibility at a university teaching hospital in Nairobi, kenya: a cross-sectional study[J]. Annals Clin Microbiol Antimicrobials. 2016;15(1):21.","journal-title":"Annals Clin Microbiol Antimicrobials"},{"issue":"5","key":"12560_CR40","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/FTD.0000000000000190","volume":"37","author":"A Hahn","year":"2015","unstructured":"Hahn A, Frenck RW Jr., Allen-Staat M, et al. Evaluation of target attainment of Vancomycin area under the curve in children with Methicillin-Resistant Staphylococcus aureus bacteremia. Ther Drug Monit. 2015;37(5):619\u201325.","journal-title":"Ther Drug Monit"},{"key":"12560_CR41","doi-asserted-by":"publisher","first-page":"S363","DOI":"10.1093\/cid\/ciaa1536","volume":"71","author":"N He","year":"2020","unstructured":"He N, Su S, Ye ZK, et al. Evidence-based guideline for therapeutic drug monitoring of vancomycin: 2020 update by the division of therapeutic drug Monitoring, Chinese Pharmacological Society[J]. Clin Infect Dis. 2020;71:S363\u201371.","journal-title":"Clin Infect Dis"},{"key":"12560_CR42","doi-asserted-by":"crossref","unstructured":"Giulia DA, Adriana CM, Chiara DW, et al. Infection control and prevention measures to reduce the spread of vancomycin-resistant enterococci in hospitalized patients: a systematic review and meta-analysis[J]. J Antimicrob Chemother. 2014;(5): 1185\u201392.","DOI":"10.1093\/jac\/dkt525"},{"key":"12560_CR43","doi-asserted-by":"crossref","unstructured":"Verrall AJ, Ryan L, Tam VH et al. Efficacy of continuous infusion of Vancomycin for the outpatient treatment of methicillin-resistant Staphylococcus aureus infections[J]. J Antimicrob Chemother. 2012;(12): 2970\u20133.","DOI":"10.1093\/jac\/dks328"},{"issue":"1","key":"12560_CR44","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S2352-4642(21)00305-9","volume":"6","author":"LF Hill","year":"2022","unstructured":"Hill LF, Clements MN, Turner MA, et al. Optimised versus standard dosing of Vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial. Lancet Child Adolesc Health. 2022;6(1):49\u201359.","journal-title":"Lancet Child Adolesc Health"}],"updated-by":[{"DOI":"10.1186\/s12879-026-13271-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000}}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12560-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-12560-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-12560-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:35:31Z","timestamp":1776404131000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-12560-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12560"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-12560-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"27 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been updated to correct and include the author\u2019s name in the author list.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12879-026-13271-0","URL":"https:\/\/doi.org\/10.1186\/s12879-026-13271-0","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study strictly adhered to the ethical principles of the Declaration of Helsinki and CONSORT guidelines for reporting clinical trials. All study protocols were approved by the Capital Institute of Pediatrics Research Ethics Committee on August 10, 2017 (NO. SHERLL2016090). Informed consent was obtained from all participants or their legal guardians prior to enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"410"}}